Background: New drugs that target the basic defect in cystic fibrosis (CF) patients may now be used in a large number of patients carrying responsive mutations. Nevertheless, further research is needed to extend the benefit of these treatments to patients with rare mutations that are still uncharacterized in vitro and that are not included in clinical trials. For this purpose, ex vivo models are necessary to preliminary assessing the effect of CFTR modulators in these cases. Method: We report the clinical effectiveness of lumacaftor/ivacaftor therapy prescribed to a CF child with a rare genetic profile (p.Phe508del/p.Gly970Asp) after testing the drug on nasal epithelial cells. We observed a significant drop of the sweat chloride value, as of the lung clearance index. A longer follow-up period is needed to define the effects of therapy on pancreatic status, although an increase of the fecal elastase values was found. Conclusion: Drug response obtained on nasal epithelial cells correlates with changes in vivo therapeutic endpoints and can be a predictor of clinical efficacy of novel drugs especially in pediatric patients.

Ex vivo model predicted in vivo efficacy of CFTR modulator therapy in a child with rare genotype / Terlizzi, V.; Amato, F.; Castellani, C.; Ferrari, B.; Galietta, L. J. V.; Castaldo, G.; Taccetti, G.. - In: MOLECULAR GENETICS & GENOMIC MEDICINE. - ISSN 2324-9269. - 9:4(2021), p. e1656. [10.1002/mgg3.1656]

Ex vivo model predicted in vivo efficacy of CFTR modulator therapy in a child with rare genotype

Amato F.;Galietta L. J. V.;Castaldo G.;
2021

Abstract

Background: New drugs that target the basic defect in cystic fibrosis (CF) patients may now be used in a large number of patients carrying responsive mutations. Nevertheless, further research is needed to extend the benefit of these treatments to patients with rare mutations that are still uncharacterized in vitro and that are not included in clinical trials. For this purpose, ex vivo models are necessary to preliminary assessing the effect of CFTR modulators in these cases. Method: We report the clinical effectiveness of lumacaftor/ivacaftor therapy prescribed to a CF child with a rare genetic profile (p.Phe508del/p.Gly970Asp) after testing the drug on nasal epithelial cells. We observed a significant drop of the sweat chloride value, as of the lung clearance index. A longer follow-up period is needed to define the effects of therapy on pancreatic status, although an increase of the fecal elastase values was found. Conclusion: Drug response obtained on nasal epithelial cells correlates with changes in vivo therapeutic endpoints and can be a predictor of clinical efficacy of novel drugs especially in pediatric patients.
2021
Ex vivo model predicted in vivo efficacy of CFTR modulator therapy in a child with rare genotype / Terlizzi, V.; Amato, F.; Castellani, C.; Ferrari, B.; Galietta, L. J. V.; Castaldo, G.; Taccetti, G.. - In: MOLECULAR GENETICS & GENOMIC MEDICINE. - ISSN 2324-9269. - 9:4(2021), p. e1656. [10.1002/mgg3.1656]
File in questo prodotto:
File Dimensione Formato  
43-2021-Terlizzi-G970D.pdf

accesso aperto

Tipologia: Versione Editoriale (PDF)
Licenza: Dominio pubblico
Dimensione 263.94 kB
Formato Adobe PDF
263.94 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/852529
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 25
  • ???jsp.display-item.citation.isi??? 21
social impact